**Supplementary Table 2.** Subgroup analysis with dapagliflozin-treated participants stratified by the presence of severe hepatic steatosis and significant liver fibrosis at baseline (*n* = 30)

| Liver parameters at baseline | No. | Baseline       | Week 24       | Paired t-test |
|------------------------------|-----|----------------|---------------|---------------|
| **CAP ≤279 dB/m**           |     |                |               |               |
| CAP                          | 12  | 237 ± 18.4     | 233 ± 43.0    | 0.755         |
| LSa                          | 12  | 4.1 (3.4–8.0)  | 4.8 (3.4–5.4) | 0.677         |
| **CAP >279 dB/m**           |     |                |               |               |
| CAP                          | 18  | 317 ± 32.1     | 290 ± 42.5    | 0.008         |
| LSa                          | 18  | 6.2 (5.6–9.4)  | 5.4 (4.8–6.9) | 0.001         |
| **LS <5.8 kPa**             |     |                |               |               |
| CAP                          | 15  | 264 ± 42.7     | 260 ± 59.0    | 0.742         |
| LSa                          | 15  | 4.4 (3.5–5.3)  | 4.6 (3.6–4.9) | 0.915         |
| **LS ≥5.8 kPa**             |     |                |               |               |
| CAP                          | 15  | 307 ± 45.1     | 275 ± 43.5    | <0.001        |
| LSa                          | 15  | 8.9 (6.3–10.4) | 6.7 (5.4–8.0) | 0.008         |

Values are presented as mean ± standard deviation or median (interquartile range). Severe hepatic steatosis was defined as CAP >279 dB/m; Significant liver fibrosis was defined as LS ≥5.8 kPa. 
CAP, controlled attenuation parameter; LS, liver stiffness. 
*Log-transformed before analysis.